Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model.

Frontiers in immunology - 1 Jan 2024

Bergman Daniel R, Wang Yixuan, Trujillo Erica, Fernald Anthony A, Li Lie, Pearson Alexander T, Sweis Randy F, Jackson Trachette L

Abstract excerpt

Bladder cancer is an increasingly prevalent global disease that continues to cause morbidity and mortality despite recent advances in treatment. Immune checkpoint inhibitors (ICI) and fibroblast growth factor receptor (FGFR)-targeted therapeutics have had modest success in bladder cancer when used as monotherapy. Emerging data suggests that the combination of these two therapies could lead to improved clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to FGFR3 gene

Share to Mutation

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Signal Transduction

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38515743
DOI: 10.3389/fimmu.2024.1358019
PMCID: PMC10954792

Genes

FGFR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model.PMID 38515743Read ↗

A Validated Mathematical Model of FGFR3-Mediated Tumor Growth Reveals Pathways to Harness the Benefits of Combination Targeted Therapy and Immunotherapy in Bladder CancerSemantic proximity Read ↗

A multiscale model of immune surveillance in micrometastases: towards cancer patient digital twinsSemantic proximity Read ↗

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.Semantic proximity Read ↗

Agent-Based Modeling of Virtual Tumors Reveals the Critical Influence of Microenvironmental Complexity on Immunotherapy EfficacySemantic proximity Read ↗

A Multifactorial Model of T Cell Expansion and Durable Clinical Benefit in Response to a PD-L1 InhibitorSemantic proximity Read ↗

Modeling the effects of EMT-immune dynamics on epithelial cancer progressionSemantic proximity Read ↗

Spatial and Functional Heterogeneities Shape Collective Behavior of Tumor-Immune NetworksSemantic proximity Read ↗

Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.Semantic proximity Read ↗

Immunodominance Hierarchy of Endogenous BBN963 Bladder Cancer Antigens Remains Stable Under Anti-PD1 and Anti-CTLA4 ImmunotherapySemantic proximity Read ↗

Personalized Immunotherapy via Multiscale Tumor-Immune Modeling and Optimal ControlSemantic proximity Read ↗

Modeling adaptive therapy in non-muscle invasive bladder cancerSemantic proximity Read ↗

Modular mechanistic mathematical models for improved biomarker identification and treatment scheduling in oncologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.